Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Betterlife Pharma Inc
(CSE:
BETR
)
0.1150
+0.0050 (+4.55%)
Official Closing Price
Updated: 1:27 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Betterlife Pharma Inc
BetterLife Announces Closing of a Private Placement
July 02, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of a Private Placement
June 14, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
June 26, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
May 14, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Intent to Complete Private Placement of Units
May 03, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Advances BETR-001 IND-enabling Studies
May 01, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 11, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
January 02, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
April 03, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of a Private Placement
December 18, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
March 04, 2024
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Extension of Warrants
November 30, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
November 15, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Pharma to Host Investors Update Call on September 18, 2023
September 14, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
September 12, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Better Home & Finance Announces Closing of Business Combination
August 23, 2023
From
Better Home & Finance
Via
Business Wire
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
June 27, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
September 05, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
June 08, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
July 13, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
June 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
March 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
April 25, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
January 26, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
March 29, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of Private Placement
December 07, 2022
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
March 09, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!
November 15, 2021
Image Provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
December 02, 2022
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.